Blogvesting

Viropharma recently acquired Lev Pharmaceuticals for $443 million ($2.75 per Lev share), primarily for its orphan drug Cinryze, which is used to treat HAE (hereditary angioedema). There are additional payouts of $0.50 per share if Cinryze gets approved by the FDA, and another $0.50 per share if total sales of Cinryze reaches $600 million within [...]

[Read more →]

Recently, I took advantage of an over-reaction in one of my favorite stocks to buy into a great company. Yum! Brands is the second largest fast food restaurant operator in the US, after MCD, with brands such as KFC, Taco Bell, Pizza Hut, Long John Silver’s, and A&W. In recent months, its stock price has [...]

[Read more →]

Despite having execution problems and ferocious competition (detailed in my last article), NVDA, I still think that NVDA will still be at least moderately profitable in the long-term, and the 30% drop in its stock price following one bad quarter is an over-reaction. NVDA has several factors in its favor.
NVDA is unlikely to lose market [...]

[Read more →]

Nvidia (NVDA) is the company which pioneered the development of the GPU, a class of chips dedicated to graphics processing and found at the heart of all displays cards. Nvidia’s stock took a dramatic dive right after its recent earnings call that revealed 3 major problems. Firstly, some of its laptop display cards are failing [...]

[Read more →]

Following my previous article on the business model of LPSN, I now present a financial analysis of the company.
In 2007, LPSN had revenues of $52.2 million, and the last quarter of that fiscal year includes revenues from the Kasamba acquisition. Of that revenue, $49.4 million is from its SaaS business, and $2.8 million is one [...]

[Read more →]